
# Sharekhan by BNP PARIBAS



Powered by the Sharekhan 3R Research Philosophy



Reco/View	Change
Reco: Buy	$\Leftrightarrow$
CMP: <b>Rs. 6,207</b>	
Price Target: Rs. 7,200	$\uparrow$
↑ Upgrade ↔ Maintain	↓ Downgrade

#### **Company details**

Market cap:	Rs. 179,169 cr
52-week high/low:	Rs. 6586/2913
NSE volume: (No of shares)	6.0 lakh
BSE code:	532538
NSE code:	ULTRACEMCO
Free float: (No of shares)	11.6 cr

#### Shareholding (%)

Promoters	60.0
FII	16.8
DII	14.3
Others	9.0

#### Price chart



#### Price performance

(%)	1m	3m	6m	<b>12</b> m
Absolute	11.9	27.5	49.6	40.1
Relative to Sensex	9.7	11.5	16.5	16.5
Sharekhan Research. Bloomberg				

# **UltraTech Cement Limited**

#### Deriving benefits of being the sector leader

Cement Sharekhan code: OLIRACEMCO Company Opdate	Cement	Sharekhan code: ULTRACEMCO	Company Update
--	--------	----------------------------	----------------

#### Summary

- We maintain Buy on UltraTech Cement (UltraTech) with a revised PT of Rs. 7,200.
- Expect healthy demand-led by pick up in non-trade demand along with sustained pricing discipline to benefit in Q4FY2021. Long-term structural demand intact.
- Impact of rise in pet coke and diesel prices to be partially felt in Q4FY2021 and fully in Q1FY2022. Higher rail transport to minimise the impact of diesel price rise.
- The company's 19.5 mtpa expansion plan at a cost of Rs. 6,527 crore (without affecting deleveraging plan) to ensure industry outperformance over the next four to five years.

UltraTech Cement (UltraTech) is expected to benefit from higher cement demand and stable cement prices although impact of rising pet coke prices is expected to partially impact in Q4FY2021 and fully in Q1FY2022. For Q3FY2021, as per Department for Promotion of Industry and Internal Trade (DPIIT), cement production declined by 4.9% y-o-y with December 2020 production rising by 8.9% m-o-m. However, our coverage universe saw strong volume growth of 7.7% y-o-y with UltraTech reporting one of the best volume growth numbers (up 14.1% y-o-y). Further, cement demand is expected to remain healthy during Q4FY2021 as non-trade demand has started to pick up along with sustained demand emanating from IHB and rural segments. Cement transported through rail during January 2021 has risen by 14.4% y-o-y (up 4.5% m-o-m). As per our channel checks, pan-India average cement prices in January-February 2021 are higher by 2.8% compared to Q4FY2020, with southern region prices up 12.9%. Barring the southern region, average cement prices have remained flat y-o-y. Industry-leading volume growth along with stable pricing environment is expected to benefit UltraTech in maintaining revenue growth for Q4FY2021. On the key input cost front, international average petcoke prices for January-February 2021 are up 9.5% versus Q3FY2021 (up 54% versus Q4FY2020), while domestic pet coke prices for the same period are up 28% versus Q3FY2021 (up 68% versus Q4FY2020). The rise in pet coke prices is expected to reflect partially in Q4FY2021 and fully in Q1FY2022 as low-cost inventory gets exhausted. Further, average retail diesel prices across metros for January-February 2021 have risen by 6.5% versus Q3FY2021 (up 19% versus Q4FY2020). However, rail freight for January-February 2021 declined by 1.8% versus Q4FY2020 and 1% versus Q3FY2021. Freight cost of cement companies is partially saved through higher transportation of cement through the rail network. On the longer term, we expect UltraTech to benefit from growth momentum picking up, as the government's focus continues on infrastructure investments (as highlighted during the recent budget). The company's 19.5 mtpa expansion plan at a cost of Rs. 6,527 crore (without affecting its current de-leveraging plan) would ensure its industry outperformance over the next four to five years. Hence, we continue to maintain our Buy rating on the stock with a revised price target (PT) of Rs. 7,200.

#### Our Call

**Valuation –Maintain Buy with a revised PT of Rs. 7,200:** UltraTech continues to post one of the leading industry volume growth numbers for Q3FY2021. Further, demand outlook remains buoyant with non-trade demand joining the bandwagon. Further, its ongoing capex plan is expected to provide the next leg of growth with the government's focus continuing to remain on infrastructure investments and the housing sector. Improving demand and limited capacity additions are expected to maintain healthy pricing discipline in the sector going ahead. Hence, we continue to maintain our Buy rating on the stock with a revised PT of Rs. 7,200.

#### Key Risks

Weak macro environment leading to lower cement demand and pressure on cement prices negatively affects profitability.

Valuation (Standalone)				Rs cr
Particulars	FY20	FY21E	FY22E	FY23E
Revenue	40,649	41,131	46,484	52,492
OPM (%)	23.1%	26.1%	25.5%	25.7%
Adjusted PAT	3,652	4,687	5,413	6,449
% YoY growth	44.6%	28.3%	15.5%	19.1%
Adjusted EPS (Rs.)	126.5	162.4	187.5	223.4
P/E (x)	49.1	38.2	33.1	27.8
P/B (x)	4.7	4.2	3.8	3.3
EV/EBITDA (x)	21.6	18.5	16.3	13.7
RoNW (%)	10.2%	11.6%	12.0%	12.7%
RoCE (%)	8.8%	9.5%	10.2%	11.1%


Source: Company; Sharekhan estimates


Stock Update

#### UltraTech to benefit from industry-leading growth and stable cement pricing environment

For Q3FY2021, as per DPIIT, cement production declined by 4.9% y-o-y with December 2020 production rising by 8.9% m-o-m. However, our coverage universe saw strong volume growth of 7.7% y-o-y with UltraTech reporting one of the best volume growth numbers (up 14.1% y-o-y). Further, cement demand is expected to remain healthy during Q4FY2021, as non-trade demand has started to pick up along with sustained demand emanating from IHB and rural segments. Cement transported through rail during January 2021 has risen by 14.4% y-o-y (up 4.5% m-o-m). As per our channel checks, pan-India average cement prices in January-February 2021 are higher by 2.8% compared to Q4FY2020 with southern region prices up 12.9%. Barring the southern region, average cement prices have remained flat y-o-y. Industry-leading volume growth along with stable pricing environment is expected to benefit UltraTech in maintaining revenue growth for Q4FY2021.

#### **Cement Production Trend**






Source: Industry; Sharekhan Research


#### Rise in pet coke prices to fully reflect in Q1FY2022; Freight costs partially saved through rail transport

International average petcoke prices for January-February 2021 are up 9.5% versus Q3FY2021 (up 54% versus Q4FY2020), while domestic pet coke prices for the same period are up 28% versus Q3FY2021 (up 68% versus Q4FY2020). Rise in pet coke prices is expected to reflect partially in Q4FY2021 and fully in Q1FY2022 as low-cost inventory gets exhausted. Further, average retail diesel prices across metros for January-February 2021 have risen by 6.5% versus Q3FY2021 (up 19% versus Q4FY2020). However, rail freight for January-February 2021 declined by 1.8% versus Q4FY2020 and 1% versus Q3FY2021. Freight costs of cement companies is partially saved through higher transportation of cement through the rail network.




### International petcoke price trend

#### **Retail Diesel Price Trend**






#### Domestic petcoke price trends



Source: Industru: Sharekhan Research

Railways cement lead distance and freight trend



Source: Ministry of Railways; Sharekhan Research

Source: DIPP; Sharekhan Research

Source: Industru: Sharekhan Research

# Understanding the Sharekhan 3R Matrix

<b>Right Sector</b>	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
<b>Right Quality</b>	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet
<b>Right Valuation</b>	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

# Sharekhan

by BNP PARIBAS

Know more about our products and services

#### For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.